Resveratrol overcomes TRAIL resistance in human colon cancer cells

Authors

  • Xiao-Bing Li Department of Oncology, Xinyu People's Hospital, China
  • Yun-Gang Deng Department of Stomach Enterochirurgia Gastrointestinal Surgery, The First Affiliated Hospital of Gannan Medical University, China
  • Jia-Ping Hu Department of General Five, The First Affiliated Hospital of Nanchang University, China
  • Zhi Wang Department of Oncology, Jiujiang First People's Hospital, China
  • Rong-Zhen Xie Department of Stomach Enterochirurgia Gastrointestinal Surgery, The First Affiliated Hospital of Gannan Medical University, China
  • Hong Luo Department of Oncology, Jiangxi Shangrao People's Hospital, China
  • Xiao-Yun Hu Department of General surgery, The 2nd Affiliated Hospital of Nanchang University, China

DOI:

https://doi.org/10.3329/bjp.v10i3.21208

Keywords:

Colon cancer, Resveratrol

Abstract

Resveratrol is a stilbenoid compound, and a promising potent chemopreventive bioactive agent. Here, we showed for the first time that the combined treatment with resveratrol and TRAIL drastically induced apoptosis in human colon cancer cells when compared to single treatments. Further, resveratrol markedly up-regulated TRAIL receptors, DR5 and DR4 and the results revealed that DR5 siRNA efficiently blocked apoptosis induced by the co-treatment with resveratrol and TRAIL, indicating that DR5 up-regulation by resveratrol helps to enhance TRAIL actions. In addition, the combined effect was tested on normal human cells. All the obtained results suggested that resveratrol is very useful for TRAIL-based treatments for cancer.

Downloads

Download data is not yet available.
Abstract
309
Download
158 Read
156

Downloads

Additional Files

Published

2015-07-02

How to Cite

Li, X.-B., Y.-G. Deng, J.-P. Hu, Z. Wang, R.-Z. Xie, H. Luo, and X.-Y. Hu. “Resveratrol Overcomes TRAIL Resistance in Human Colon Cancer Cells”. Bangladesh Journal of Pharmacology, vol. 10, no. 3, July 2015, pp. 568-76, doi:10.3329/bjp.v10i3.21208.

Issue

Vol. 10 No. 3 (2015)

Section

Research Articles

License

Authors who publish with this journal agree to the following terms:

  1. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
  2. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
  3. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).